Mfd. by :- Hetero (Fulfilled By : Magicine Pharma)
Magicine Pharma is registered with the Government Of NCT, India, Ministry Of Health in Government of Delhi, India, registration number DL-RAJ-122372 and as a wholesale distributor, department file No. 44208.
Medicine details
Brand name - Mozifor
Generic name - Plerixafor
Manufacturer - Hetero Drugs Ltd
Salt composition - Plerixafor (24mg)
Storage - Store at room temperature (10-30°C)
Dosage form - Injection
Strength - 1.2 ml
Packaging - Vial
Gender - Unisex
Indication - Used in the treatment of Multiple myeloma, Non-hodgkin’s lymphoma and other related conditions
Mozifor injection is used in the treatment of Multiple myeloma, Non-hodgkin’s lymphoma, and other related conditions. It is used in Autologous stem cell transplant. In this procedure, certain blood cells are removed from the body and then returned back to the body after the chemotherapy and/or radiation in patients with certain types of cancers.
Plerixafor is an hematopoietic stem cell mobilizer. It works by moving certain blood cells from the bone marrow to the blood so that those cells can be removed for transplant. Plerixafor is an inhibitor of the CXCR4 chemokine receptor. It blocks the binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α & CXCR4 play a role in the trafficking & homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can work to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. Treatment with Plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in humans. CD34+ cells mobilized by Plerixafor are capable of engraftment with long-term repopulating capacity up to one year in canine transplantation models.
Data on the fold increase in peripheral blood CD34+ cell count (cells/mcL) by apheresis day was evaluated in two placebo-controlled clinical studies in patients with NHL and MM. The fold increase in CD34+ cell count (cells/mcL) over the 24-hour period starting from the day prior to the first apheresis and ending the next morning just before the first apheresis was noted. During this 24-hour period, a single dose of placebo was administered 10 to 11 hours prior to apheresis.
Peak mobilization of CD34+ cells was observed between 6 and 9 hours after administration. A sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with a peak CD34+ count between 10 and 14 hours.
The active ingredient in Mozifor is Plerixafor.
Mozifor injection is used in the treatment of Multiple myeloma, Non-hodgkin’s lymphoma and other related conditions. It is used in Autologous stem cell transplant.
Celrixafor Injection
Plerimob 24mg Injection
Diarrhea
Nausea
Fatigue
Injection site reactions
Headache
Dizziness
Vomiting
Arthralgia
Breathing problem
Your healthcare provider will decide your dose according to your medical condition and requirement.
Do not take the missed dose if it is already time for the next dose. Do not double the dose to catch up.
Please consult your healthcare provider regarding any symptoms of overdose.
Avoid consuming alcohol.
Avoid driving or operating machines as this medicine may cause dizziness and vomiting.
Tell your healthcare provider if you have any allergy or liver disease or kidney disease or if you take any other medication.
Please consult your healthcare provider regarding the consumption of Mozifor injection during breastfeeding.
Tell your healthcare provider if you are planning to get pregnant or breastfeeding.
A- Mozifor injection is used in the treatment of Multiple myeloma, Non-hodgkin’s lymphoma and other related conditions.
A- Your healthcare provider will give you this medicine. Kindly do not self administer.
A- There can be side effects such as diarrhea, nausea, fatigue, headache, dizziness, vomiting and injection site reaction. Please consult your healthcare provider if you experience these or any other side effects.
A- It is available in the strength of 1.2ml.
A- If it is already time for the next dose, do not take the previous dose. Do not double the dose to catch up. Also, inform your healthcare provider.
A- Avoid drinking alcohol.
A- Note every side effect and consult your healthcare provider for the same as soon as you can.
A- Mozifor injection may cause harm to the developing baby. Please consult your healthcare provider for the same.
A- Mozifor injection may make you drowsy. Avoid driving and operating heavy machines.
A- Store at room temperature (10-30°C).
A- There is not much information available about this medicine with respect to liver disease. Please consult your healthcare provider.
A- In patients with kidney disease, Mozifor injection’s dose may be adjusted. Please consult your healthcare provider for the appropriate dose details.
A- It is not known whether it is safe to consume alcohol with Mozifor injection. Please consult your healthcare provider.
Fill the Form
Talk to Executive
Get Tracking
Get Medicines Delivered
